santen (201050): A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of a tafluprost 0.0015% and timolol 0.5% eye drop given as individual monotherapies in patients with open-angle glaucoma or ocular hypertension